Refractory Non-Hodgkin Lymphoma Clinical Trials in New York, New York

4 studies are recruiting for refractory non-hodgkin lymphoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

2. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

   This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   35 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05826535 on ClinicalTrials.gov

3. Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

   This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory)…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   7 in total

   Run by

   AIDS Malignancy Consortium

   See if you can join NCT05077527 on ClinicalTrials.gov

4. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

   This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYP/Weill Cornell Medical Center, New York, New York

   Locations

   12 in total

   Run by

   Indapta Therapeutics, INC.

   See if you can join NCT06119685 on ClinicalTrials.gov